Inhibition of intestinal disaccharidases and suppression of blood glucose by a new alpha-glucohydrolase inhibitor--MDL 25,637.
MDL 25,637 is a novel compound designed as a transition-state inhibitor of alpha-glucohydrolases. This compound inhibits rat intestinal sucrase, maltase, isomaltase, glucoamylase and trehalase activities at micromolar concentrations. It is a much weaker inhibitor of alpha-amylase and lactase. Inhibition of sucrase was competitive with sucrose. In mice, MDL 25,637 inhibited the rise in serum glucose after a sucrose or starch load but not after a glucose load. MDL 25,637 also reduced the glycemic response to sucrose in rats. The drug was most effective when administered 0 to 30 min before the sucrose load and was as effective in streptozotocin-treated rats as in normals. The inhibition by MDL 25,637 of intestinal glucohydrolases is an effective means of reducing the hyperglycemic response to an oral sucrose or starch load and, as such, warrants further investigation as a potential drug for the treatment of diabetes mellitus.
Rhinehart
B L
BL
Robinson
K M
KM
Liu
P S
PS
Payne
A J
AJ
Wheatley
M E
ME
Wagner
S R
SR
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D004186:Disaccharidases / Q000037:antagonists & inhibitors*; D005769:Gastrointestinal Motility / Q000187:drug effects; D007328:Insulin / Q000097:blood; D007422:Intestines / Q000201:enzymology*; D051381:Rats; D013402:Sugar Alcohols / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D013402:Sugar Alcohols; C052772:MDL 25637; D004186:Disaccharidases